DBT funded project positions for Life sciences candidates at RCB
6 May 2026

DBT funded project positions for Life sciences candidates at RCB

PhD or equivalent degree in Life Sciences with at least one research paper in Science Citation Indexed journal.
Dr. Reddy’s Lab Career-Expo for Pharma and Science candidates
6 May 2026
Dr. Reddy’s Lab Career-Expo for Pharma and Science candidates
Sterile equipment qualification experience with SAT, IQ, OQ, PQexecution, including autoclave, tunnel, filling/capping machines, Lyo, washing and related systems.
Production, Warehouse and Packaging & Development Openings at Natco Pharma
6 May 2026
Production, Warehouse and Packaging & Development Openings at Natco Pharma
B.Pharm with P.G Diploma in Packaging from IIP ; Diploma / B. Pharmacy / M. Pharmacy
Opportunities in Quality Function for Sciences / Pharmacy candidates at Pfizer
6 May 2026
Opportunities in Quality Function for Sciences / Pharmacy candidates at Pfizer
Serve on cross-functional teams, conduct safety inspections, participate in investigations, recommend corrective actions, and train junior colleagues.
Walk In Drive for Production, QC, QA Department at CORONA Remedies
6 May 2026
Walk In Drive for Production, QC, QA Department at CORONA Remedies
Analysis of Raw Material, In-process, Finish Products, Stability Tastings. Process Validation, participate in Lab incident/OOS/OOT/Analytical deviation.
QC, QA, Production Jobs at Gracure Pharmaceutical | B.Pharma / M.Pharma / MSc job role
6 May 2026
QC, QA, Production Jobs at Gracure Pharmaceutical | B.Pharma / M.Pharma / MSc job role
B.Pharma/ M.Pharma/ Msc; Relevant functional experience in regulatory approved facilities at Gracure Pharmaceutical
Gufic Biosciences Hiring Pharma, Chemistry, Microbiology, Biotechnology professionals
6 May 2026
Gufic Biosciences Hiring Pharma, Chemistry, Microbiology, Biotechnology professionals
M.Pharm / B.Pharm / D.Pharm / M.Sc (Chemistry/Organic Chemistry / Microbiology, Biotechnology) 
Lilly’s Omvoh Shows 4-Year Durable Disease Clearance in Ulcerative Colitis
6 May 2026
Lilly’s Omvoh Shows 4-Year Durable Disease Clearance in Ulcerative Colitis

New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease clearance through four years of continuous treatment. In the LUCENT-3 open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years.

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
6 May 2026
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
Johnson & Johnson announced results from the first clinical study of the investigational OTTAVA™ Robotic Surgical System – a prospective, multicenter clinical study evaluating the safety and performance of the system in Roux-en-Y gastric bypass procedures.
JNJ announces Phase 2b data from two studies evaluating JNJ-4804
6 May 2026
JNJ announces Phase 2b data from two studies evaluating JNJ-4804

Johnson & Johnson announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF-α), in patients with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) that is refractory to systemic therapies.1,2 The late-breaking presentations from the DUET-UC and DUET-CD studies were among the 32 company-sponsored abstracts being presented at Digestive Disease Week (DDW) 2026.